Synergistic epistasis of paraoxonase 1 (rs662 and rs85460) and apolipoprotein E4 genes in pathogenesis of Alzheimer's disease and vascular dementia

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 8, 2014, Pages 769-776

  Alam, Rizwan ^a,b   Tripathi, Manjari ^a   Mansoori, Nasim ^a   Parveen, Shama ^b   Luthra, Kalpana ^a   Lakshmy, Ramakrishnan ^a   Sharma, Subhadra ^a   Arulselvi, Subramanian ^a   Mukhopadhyay, Asok K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Alzheimer's disease; apolipoprotein; lipid profile; paraoxonase; synergistic epistasis; vascular dementia

Indexed keywords

APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE 1; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PON1 PROTEIN, HUMAN; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA EXTRACTION; EPISTASIS; GENE FREQUENCY; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; PATHOGENESIS; RISK ASSESSMENT; AGED; BLOOD; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEMENTIA, VASCULAR; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84911401014     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317514539541     Document Type: Article

References (42)

1. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer's disease. Neurobiol Aging. 2009 ; 30 ((9)). 1333-1349
2. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006 ; 187 ((1)). 74-81
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 ; 320 ((14)). 915-924
4. Holvoet P, Peeters K, Lund-Katz S, et al. Arg123-Tyr166 domain of human ApoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2001 ; 21 ((12)). 1977-1983
5. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1989 ; 86 ((3)). 1046-1050
6. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991 ; 88 ((6)). 1785-1792
7. Kalman J, Kudchodkar BJ, Murray K, et al. Evaluation of serum - lipid -related cardiovascular risk factors in Alzheimer's disease. Dement Geriatr Cogn Disord. 1999 ; 10 ((6)). 488-493
8. Schippling S, Kontush A, Arlt S, et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med. 2000 ; 28 ((3)). 351-360
9. Mansoori N, Tripathi M, Luthra K, et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer's and vascular dementia and their epistatic interaction. Neurobiol Aging. 2011 1003 ; 33 ((5)). e1 - e8
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 ; 16 ((3)). 1215
11. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993 ; 52 ((3)). 598-608
12. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 ; 3 ((1)). 73-76
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18 ((6)). 499-502
14. Ombres D, Pannitteri G, Montali A, et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol. 1998 ; 18 ((10)). 1611-1616
15. Shin BS. Paraoxonase gene polymorphism in south-western Korean population. J Korean Med Sci. 2009 ; 24 ((4)). 561-566
16. Yamada Y, Ando F, Niino N, Miki T, Shimokata H. Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J Hum Genet. 2003 ; 48 ((9)). 469-475
17. Lakshmy R, Ahmad D, Abraham RA, et al. Paraoxonase gene Q192R & L55 M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res. 2010 ; 131: 522-529
18. Wang X, Fan Z, Huang J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 2003 ; 23 ((2)). 328-334
19. Li W-F, Pan MH, Chung MC, Ho CK, Chuang HY. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ Health Perspect. 2006 ; 114 ((8)). 1233-1236
20. Pola R, Gaetani E, Flex A, et al. Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Dement Geriatr Cogn Disord. 2003 ; 15 ((2)). 88-91
21. Shi JJ, Zhang SZ, Ma C, et al. Gln192Arg polymorphism of the paraoxonase-1 gene is not associated with Alzheimer's disease in Chinese. Di Yi Jun Yi Da Xue Xue Bao. 2004 ; 24 ((4)). 371-374
22. Sodeyama N, Yamada M, Itoh Y, et al. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology. 1999 ; 53 ((5)). 1146-1148
23. Klimkowicz-Mrowiec A, Marona M, Wolkow P, et al. Paraoxonase gene polymorphism and the risk for Alzheimer's disease in the polish population. Dement Geriatr Cogn Disord. 2011 ; 31 ((6)). 417-423
24. He XM, Zhang ZX, Zhang JW, et al. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin Med J. 2006 ; 119 ((14)). 1204-1209
25. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM. Different pattern of association of paraoxonase Gln192 - >Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett. 2003 ; 339 ((1)). 17-20
26. Helbecque N, Cottel D, Codron V, Berr C, Amouyel P. Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett. 2004 ; 358 ((1)). 41-44
27. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci. 2002 ; 977: 239-244
28. Gamboa R, Zamora J, Rodríguez-Pérez JM, et al. Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp Mol Pathol. 2006 ; 80 ((1)). 85-90
29. Sirivarasai J, Kaojarern S, Yoovathaworn K, Sura T. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. Chem Biol Interact. 2007 ; 168 ((3)). 184-192
30. Leduc V, Poirier J. Polymorphisms at the paraoxonase 1 L55 M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis. 2008 ; 5 ((3-4)). 225-227
31. Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J. Codon 311 (Cys - > Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psychiatry. 2002 ; 7 ((1)). 110-112
32. Eerligh P, Koeleman BP, Dudbridge F, Jan Bruining G, Roep BO, Giphart MJ. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun. 2004 ; 5 ((1)). 36-40
33. Yamada R, Tanaka T, Unoki M, et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am J Hum Genet. 2001 ; 68 ((3)). 674-685
34. Flex A, Gaetani E, Papaleo P, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke. 2004 ; 35 ((10)). 2270-2275
35. Wingo TS, Rosen A, Cutler DJ, Lah JJ, Levey AI. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol Aging. 2012 ; 33 (1). e13 - e15
36. Cellini E, Tedde A, Bagnoli S, et al. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci Lett. 2006 ; 408 ((3)). 199-202
37. Zuliani G, Cavalieri M, Galvani M, et al. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J Gerontol A Biol Sci Med Sci. 2010 ; 65 ((5)). 559-564
38. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999 ; 282 ((3)). 254-260
39. Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004 ; 61 ((5)). 705-714
40. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxonase 1 activity: a new vascular marker of dementia?. Ann N Y Acad Sci. 2002 ; 977: 96-101
41. Paragh G, Balla P, Katona E, Seres I, Egerházi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2002 ; 252 ((2)). 63-67
42. Corrigan FM, Mowat B, Skinner ER, Van Rhijn AG, Cousland G. High density lipoprotein fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids. 1998 ; 58 ((2 )). 125-127